Nice & Green

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Lucibel is a French company that specializes in designing and manufacturing advanced lighting products and solutions utilizing LED technology. Committed to sustainability and efficiency, Lucibel's offerings are not only energy-efficient but also integrate smart features that facilitate remote management. Their innovative lighting solutions enable real-time control and measurement, allowing light to interact dynamically with its environment. Additionally, Lucibel's technology supports new forms of data transmission and enhances user well-being, positioning the company at the forefront of the digital lighting era.

LIDDS AB is a pharmaceutical company based in Uppsala, Sweden, specializing in the development of injectable drugs for cancer and other diseases. The company employs its proprietary NanoZolid® technology, which addresses key challenges in drug delivery by enabling controlled, long-term, and personalized release of medications for up to six months. LIDDS is focused on creating a range of innovative treatments, including NZ-2HOF for prostate cancer, NZ-DTX for various cancers, NZ-DOX for solid tumors, and several immunotherapy options such as NZ-IO, NZ-STING, and NZ-TLR9. Through its unique approach, LIDDS aims to improve patient quality of life by enhancing the efficacy and convenience of cancer treatments.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Endurance Motive design and implementation of sustainable energy solutions for industrial vehicles, nautical vessels and public transport. Discover the advantages of switching to Lithium.

EEMS Italia is a semiconductor manufacturer and photovoltaic panel producer with operations in China and Italy. The company focuses on providing assembly and test solutions for the semiconductor industry, specifically developing semiconductor memories. In addition to its core manufacturing business, EEMS Italia is committed to the energy sector and the Green Economy. It aims to expand its involvement by initially entering the energy transition market as a wholesaler, with plans to evolve into a multi-utility operator. EEMS Italia seeks to play a significant role in promoting and facilitating the transition to cleaner, more sustainable energy sources.

Marinomed Biotech AG is a biopharmaceutical company based in Vienna, Austria, specializing in the development of innovative therapies for respiratory and ophthalmological diseases. Founded in 2006, the company operates primarily through two technology platforms: Marinosolv and Carragelose. Marinosolv enables the creation of stable aqueous formulations for poorly soluble compounds, enhancing their bioavailability and therapeutic efficacy, while Carragelose offers antiviral solutions aimed at respiratory viruses. Marinomed's product portfolio includes nasal sprays, throat sprays, and lozenges designed to block viruses and alleviate symptoms associated with conditions such as cough, cold, influenza, and allergic rhinitis. The company collaborates with partners to market its products globally, focusing on improving treatment options for patients with sensitive tissues in the nose and eyes.

Tessellis is an Italian telecommunications operator that provides Internet and communications services to residential and business customers. The company offers broadband and narrowband Internet access, voice services, portal services, and mobile telephone services in Italy. It serves consumer and corporate markets through segments such as Access (connectivity) and Corporate. Tessellis is based in Sa Illetta, Cagliari, Sardinia.

Napster is a subscription-based music streaming service offering unlimited on-demand access to millions of songs across various platforms. It provides advertisement-free listening, along with features like playlists, reviews, and radio stations. Napster operates in the U.S., Canada, Germany, and the UK.

MelodyVR is a pioneering Virtual Reality music platform operating in the US, UK, and Europe. It holds the distinction of being the only licensed VR music platform globally, having established partnerships with all major record labels, including Universal Music Group, Sony Music Entertainment, Warner Music Group, and Roc Nation. The company has created a comprehensive end-to-end process that facilitates the entry of prominent artists into the realm of virtual reality. MelodyVR boasts the world's largest library of interactive music content, collaborating with over 650 international artists. Users are offered a unique experience with multiple perspectives, ranging from being immersed in the crowd to enjoying close-up views of performances. In addition to a vast collection of recorded shows, MelodyVR also live streams concerts in virtual reality, having partnered with several major venues in the UK. The company is based in Hitchin, United Kingdom, and has developed proprietary technology that enables the transformation of recorded material into immersive 360-degree panoramic video content.

Rapid Nutrition is a HealthTech company focused on advancing health through evidence-based, personalized nutrition solutions that leverage technology, AI, and scientific research. It develops natural nutrition products and provides research, development, and production services for evidence-based nutrition, aiming to optimize nutrition, improve wellness, and support sustainable, healthier lifestyles globally.

cyan Security Group GmbH is a Vienna-based company that specializes in the development and distribution of mobile security solutions. With over 25 years of experience in the IT security field, cyan provides customized solutions tailored to various business segments. The company operates a research and development center in Brno, Czech Republic, which fosters collaboration with universities, international institutes, and financial organizations. This close cooperation enables cyan to identify emerging trends and technological advancements, ensuring the integration of cutting-edge features into its products. As a subsidiary of cyan AG, the company leverages its parent organization's resources and expertise to enhance its offerings in the security sector.

FacePhi is the leading Spanish company in biometric solutions for identity verification, specialized in facial recognition systems, digital onboarding and safe work environments. Based in Alicante and operating worldwide, the company has a presence in more than 25 countries, has performed more than 1 trillion authentications, 21 million access programs and has a strong presence in the banking sector. The drive of biometrics to improve customer experience and protect data from citizens and entities is the hallmark of the firm.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Bublar Group is a Swedish company based in Stockholm that focuses on the development of mobile gaming through the integration of augmented reality (AR) and virtual reality (VR) technologies. The company combines smartphone capabilities with advanced 3D graphics to create engaging and interactive experiences for users, allowing them to generate personal real-time 3D objects that can be seamlessly integrated into their real-world environments. With a team experienced in simulation systems, eye-tracking, and location-based services, Bublar aims to revolutionize how users interact with digital content. Its innovative approach not only enhances mobile gaming but also positions the company at the forefront of the AR and VR industries.

Artificial Solutions International AB specializes in providing a conversational AI platform that enables users to interact with applications, websites, and devices using natural language through various inputs such as voice, text, touch, or gesture. Their Teneo platform facilitates collaboration between business users and developers to create sophisticated applications that support 35 languages and operate across multiple platforms and channels. The platform not only enhances user communication but also integrates the analysis of conversational data, offering valuable insights into customer behavior and preferences. Artificial Solutions serves a diverse range of industries, including banking, automotive, retail, telecommunications, energy, travel, and media, and is headquartered in Stockholm, Sweden. Founded in 2001, the company is recognized as a leader in enterprise-strength conversational AI.

FacePhi is the leading Spanish company in biometric solutions for identity verification, specialized in facial recognition systems, digital onboarding and safe work environments. Based in Alicante and operating worldwide, the company has a presence in more than 25 countries, has performed more than 1 trillion authentications, 21 million access programs and has a strong presence in the banking sector. The drive of biometrics to improve customer experience and protect data from citizens and entities is the hallmark of the firm.

Itway S.p.A is an Italy-based company operating in the information technology sector, specializing in cyber security solutions. The company focuses on the distribution and integration of products and services aimed at enhancing the logical security of IT systems. Itway generates most of its revenue from the Value Added Distribution segment, which includes services related to Value Added Resellers and Value Added Services. In addition to its distribution activities, Itway also engages in the production of software technologies for e-business and offers professional services as a system integrator, facilitating the centralization of applications for its clients.

WISeKey is a global cybersecurity company specializing in integrated security solutions for the Internet of Things (IoT) and digital identity ecosystems. Headquartered in Switzerland, the company leverages its patented cryptographic Root of Trust (RoT) to provide secure authentication and identification across both physical and virtual environments. WISeKey's offerings include a range of semiconductor chips, cybersecurity software, and managed public key infrastructure (PKI) services, all designed to protect users, devices, data, and transactions in an increasingly interconnected world. The company operates primarily through two business segments: the IoT segment, which focuses on the sale of secure semiconductor chips and is the main revenue driver, and the mPKI segment, which generates revenue through digital certificates. WISeKey's comprehensive solutions address significant gaps in cybersecurity and data protection, enabling clients to navigate the evolving landscape of digital devices without compromising their security.

Moberg Derma is a Swedish pharmaceutical company that focuses on commercializing proprietary, acquired, and licensed products in the global market. The company aims to deliver value to patients, healthcare professionals, and stakeholders by providing products based on proven compounds that demonstrate improved efficacy, reduced side effects, or enhanced usability. While Moberg Derma initially concentrated on treating skin diseases, it is now expanding its product offerings to include other therapeutic areas. The company markets over-the-counter brands in the United States and distributes its products in more than 35 countries worldwide.

FacePhi is the leading Spanish company in biometric solutions for identity verification, specialized in facial recognition systems, digital onboarding and safe work environments. Based in Alicante and operating worldwide, the company has a presence in more than 25 countries, has performed more than 1 trillion authentications, 21 million access programs and has a strong presence in the banking sector. The drive of biometrics to improve customer experience and protect data from citizens and entities is the hallmark of the firm.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Theraclion is a French company founded in 2004, specializing in high-tech medical equipment that utilizes high-intensity focused ultrasound (HIFU) for therapeutic purposes. It develops, manufactures, and markets innovative medical devices, notably the Echopulse®, designed for the non-invasive treatment of breast fibroadenomas and benign thyroid nodules. Additionally, the company offers the SONOVEIN®, which is aimed at treating varicose veins in the lower limbs. Theraclion’s echotherapy solutions integrate HIFU with ultrasound technology, enabling precise localization of target areas for effective treatment of benign tumors and varicose veins.

Founded in 2006, Implanet designs, manufactures, and sells high-quality orthopedic implants for surgical markets worldwide. Its product portfolio includes spinal fixation systems like Jazz, knee prostheses such as Madison, and other orthopedic devices.

SpineGuard is a French medical company specializing in radiation-free real-time sensing technology for orthopedic surgery. Its flagship product, PediGuard probes, assist spine surgeons in accurately placing pedicle screws during spinal procedures. With over 80,000 successful procedures worldwide and extensive clinical evidence, SpineGuard's devices are becoming a standard solution for safe and accurate pedicle screw placement.

Amoeba is a France-based company dedicated to the development, production, and commercialization of environmentally friendly biocide water treatment chemicals. Its primary product, BIOMEBA, utilizes the biocidal properties of the microorganism Willaertia magna to effectively address bacterial risks in cooling towers, particularly within the industrial sector. Through its innovative approach, Amoeba aims to provide sustainable solutions for water treatment challenges, positioning itself as a leader in the green biocide market.

Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.

Saniona is a pharmaceutical company focused on discovering and developing medicines that modulate ion channels to treat central nervous system disorders, autoimmune diseases, metabolic diseases, and pain. It operates a technology platform that enables investigation of ion channel targets, including GABAA receptors, nicotinic acetylcholine receptors, and potassium channels, to create selective modulators. Its product pipeline includes Tesomet, SAN711, SAN903, and SAN2219; Tesomet has advanced to mid-stage trials for rare eating disorders, SAN711 completed a Phase 1 trial for neuropathic pain, SAN903 is positioned to enter Phase 1 trials for inflammatory and fibrotic disorders, and SAN2219 is in development. Saniona operates in the United States, Sweden, Germany, Denmark, and the United Kingdom.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.